

(I)

<u>either</u> R_1 is hydrogen or methyl and R_2 is selected from the group consisting of cyclohexyl substituted by an amine, $CH_2CH_2NHCH_3$, $CH_2CHCH_3NH_2$,

 ,  , 

 ,  , 

$CHCH_3CH_2NH_2$, -(CH2)aOH where a is an integer of 1 to 8, (CH_2)b-C≡N where

b is an integer of 1 to 8, $CHCH_3C_6H_5$, (CH_2)-$C(CH_3)_2NHCOCF_3$, and $CHCH_3(CH_2)$dOH where d is an integer of 1 to 8

<u>or</u> R_1 and R_2 together with the nitrogen to which they are attached

form a ring of 3, 4 or 5 carbons optionally substituted by an amine

R_3 is selected from the group consisting of hydrogen, methyl and hydroxyl

R_4 is hydrogen or hydroxyl,

R is selected from the group consisting of alkyl and cycloalkyl of up to 30 carbon atoms, optionally containing at least one heteroatom, at least one heterocycle and alkyl or cyclic acyl of up to 30 carbon atoms optionally containing at least one heteroatom, and/or at least one heterocycle,

T is selected from the group consisting of hydrogen, methyl, $-CH_2CONH_2$, $-CH_2C{\equiv}N$, $-(CH_2)_2NH_2$ and $-(CH_2)_2Nalk^+X^-$, X is halogen and alk is alkyl of up to 8 carbon atoms,

Y is selected from the group consisting of hydrogen, hydroxyl, halogen and $-OSO_3H$ or the salt thereof,

W is hydrogen or OH,

Z is hydrogen or methyl and its non-toxic, pharmaceutically acceptable acid addition salt.

Claim 2 (amended) A compound of claim 1 in which T is hydrogen.

Claim 3 (amended) A compound of claim 1 in which W is hydrogen.

Claim 4 (amended) A compound of claim 1 in which Z is methyl.

Claim 5 (amended) A compound of claim 1 in which Y is hydrogen.

Claim 6 (amended) A compound of claim 1 in which R_3 is methyl.

Claim 7 (amended) A compound of claim 1 in which R_4 is hydroxyl.

Claim 8 (amended) A compound of claim 1 in which R is selected from the group consisting of















and



Claim 9 (amended) A compound of claim 8 in which R is



Claim 10 (amended) A compound of claim 8 in which R is



Claim 11 (amended) A compound of claim 1 in which R_1 is hydrogen.

Claim 12 (amended) A compound of claim 1 in which R_2 is



Claim 13 A compound of claim 1 in which R_2 is selected from the group consisting of



Claim 14 (amended) A compound of claim 1 in which R2 is



Claim 15 (amended) A compound of claim 1 selected from the from the group consisting of

- 1-[4-[[(1H-benzimidazol-2-yl)-methyl)-amino]-N2-[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4-yl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]5-L-serine-echinocandine B trifluoroacetate (isomer B), and
- trans 1-[4-[(2-aminocyclo-hexyl)-amino]-N2-[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4-yl-carbonyl]-L-ornithine]-4-[4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate (isomer A).

Claim 16 (amended) A process for the preparation of a compound of claim 1 comprising reacting a compound of the formula



(II)

(II)

wherein R, R_3, R_4, T, Y, W and Z are defined as in claim 1 with an amine or amine derivative capable of introducing



in which R_1 and R_2

are defined as in claim 1 and optionally to the action of a reducing agent

and/or an amine functionalization agent,

and/or an acid to form the salt of the product of claim 1,

and/or a separation agent of the different isomers obtained.

Cancel claims 17 and 18 and add the following claims.